Sign In
Buy BTX
$8.05
+0.150 (+1.90%)
At Close: Jul 31, 2026
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts
08:15am, Wednesday, 15'th Sep 2021
CAMBRIDGE, Mass., Sept. 15, 2021 /PRNewswire/ -- Factor Bioscience Inc., a biotechnology company headquartered in Cambridge, Massachusetts, celebrated its tenth anniversary on September 9, 2021 with t
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum
04:15pm, Friday, 20'th Aug 2021
BROOKLYN, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and g
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021
08:30am, Friday, 20'th Aug 2021
NEW YORK, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene ed
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET
04:15pm, Monday, 16'th Aug 2021
BROOKLYN, N.Y., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and g
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021
02:22pm, Friday, 13'th Aug 2021
NEW YORK, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene ed
Brooklyn Immuno Reports Inducement Grants
04:30pm, Friday, 23'rd Jul 2021
BROOKLYN, N.Y., July 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and g
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics
08:00am, Monday, 19'th Jul 2021
Acquisition Advances Transformation Into Platform Company Focused on Cell, Gene Editing and Cytokine Therapy
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer
08:15am, Tuesday, 13'th Jul 2021
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene ed
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021
08:15am, Monday, 12'th Jul 2021
NEW YORK, July 12, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that c
7 Top-Rated Pharmaceutical Companies to Invest In for July
09:15am, Friday, 09'th Jul 2021
Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest I
Brooklyn ImmunoTherapeutics Reports Inducement Grants
05:57pm, Tuesday, 06'th Jul 2021
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics LLC (NYSE American: BTX) (“Brooklyn” or “the Company”), a biopharmaceutical company focused on exploring the role that c
7 Best Reddit Stocks to Buy If You Have $100 to Spare
09:05am, Friday, 18'th Jun 2021
Looking to roll the dice? Consider buying one (or more) of these seven high-risk, but possibly high-return, Reddit stocks.
Why Brooklyn ImmunoTherapeutics Crushed the Market Today
05:01pm, Monday, 14'th Jun 2021
The biotech is bulking up with a new acquisition.
Brooklyn ImmunoTherapeutics Stock Rises After Novellus Therapeutics Buyout Deal
12:24pm, Monday, 14'th Jun 2021
Brooklyn ImmunoTherapeutics LLC (NYSE: BTX) has executed a non-binding letter of intent to acquire Novellus Therapeutics, a company developing engineered mesenchymal stem cell (MSC) therapies using
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics
07:30am, Monday, 14'th Jun 2021
Novellus Therapeutics develops next-generation mesenchymal stem cell products using licensed patented mRNA cell reprogramming and gene editing technologies Novellus Therapeutics develops next-generati
